Date: 2012-12-19
Type of information:
Compound: cell culture media and buffers
Company: Lonza (Switzerland) Sartorius Stedim Biotech (France)
Therapeutic area:
Type agreement: development
collaboration
distribution
Action mechanism:
Disease:
Details: Lonza and Sartorius Stedim Biotech (SSB) have announced a long-term global collaboration, supply and distribution agreement in the field of cell culture media. In the agreement, SSB will assume global sales and marketing of media and buffers used in the manufacture of protein-based therapeutics and vaccines, while Lonza will continue to carry out development, manufacture and logistics operations for these products.
New product development will be mutually performed. The cell culture media, which are usually sold in liquid or powder form to biopharmaceutical customers, are to be successively converted to packaged forms as ready-to-use, pre-filled SSB sterile single-use bags. Furthermore, Lonza and SSB have agreed that these cell culture media will be sold under both brands in a co-branding arrangement. Lonza will maintain commercial responsibility for global sales and marketing of media used for research purposes and in the manufacture of cell-based therapeutics and gene therapy as well as for manufacturing for any of Lonza’s custom manufacturing customers.
In fiscal year 2011, Lonza generated revenues of approximately CHF 25 million in the field of cell culture media. SSB will take over Lonza’s commercial team of about 15 media specialists. Both parties have agreed not to disclose contractual conditions.
Financial terms:
Latest news:
